Sarepta Therapeutics Inc. (srpt 1.5 11/15/24)
13F holders, Q2 2024 (June 30)2holders −1
0new positions
1sold out
$2.16avg. 13F price*
At the end of Q2 2024, 2 institutions reported holding Sarepta Therapeutics Inc. (srpt 1.5 11/15/24) in their 13F filings, down 1 from Q1 2024. 0 opened new positions and 1 sold out. The largest holders were Boothbay Fund Management, LLC ($9.5M) and Fox Hill Wealth Management ($52K).
- Company
- Sarepta Therapeutics Inc. (srpt 1.5 11/15/24)
- CUSIP
- 803607AB6
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $4K |
All 13F filers, Q1 2024 → Q2 2024: 877,000 shares bought and 2,000 shares sold, net +875,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Boothbay Fund Management, LLC | 0.33% | Add +25.0% | 4,389,000 | $9.5M |
| Fox Hill Wealth Management | 0.03% | No change | 24,000 | $52K |
"% of holder's portfolio" is SAREPTA THERAPEUTICS INC (SRPT 1.5 11/15/24)'s weight in each manager's 13F, not the share of Sarepta Therapeutics Inc. (srpt 1.5 11/15/24) the manager owns.